Polyfunctional response by ImmTAC (IMCgp100) redirected CD8+ and CD4+ T cells

Immunology

Volumn 152, Issue 3, 2017, Pages 425-438

  Boudousquie, Caroline ^a   Bossi, Giovanna ^a   Hurst, Jacob M ^a   Rygiel, Karolina A ^a   Jakobsen, Bent K ^a   Hassan, Namir J ^a  

^a Immunocore Limited   (United Kingdom)

Author keywords

cancer; ImmTAC; immunotherapy; melanoma; T cell receptor; T cells

Indexed keywords

ANTINEOPLASTIC AGENT; GAMMA INTERFERON; GAMMA INTERFERON INDUCIBLE PROTEIN 10; GLYCOPROTEIN GP 100; GRANZYME B; IMCGP 100; INTERLEUKIN 6; MACROPHAGE INFLAMMATORY PROTEIN 1ALPHA; MACROPHAGE INFLAMMATORY PROTEIN 1BETA; MONOCYTE CHEMOTACTIC PROTEIN 1; T LYMPHOCYTE RECEPTOR; TUMOR NECROSIS FACTOR; UNCLASSIFIED DRUG; CYTOKINE; HLA A2 ANTIGEN; HLA-A*02:01 ANTIGEN; IMMTAC MOLECULE, HUMAN; MELANOCYTE PROTEIN PMEL 17; PROTEIN; SINGLE CHAIN FRAGMENT VARIABLE ANTIBODY;

APOPTOSIS; ARTICLE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL KILLING; CELL LEVEL; CONTROLLED STUDY; CYTOKINE RELEASE; EFFECTOR CELL; HUMAN; HUMAN CELL; IMMUNE RESPONSE; IN VITRO STUDY; LYMPHOCYTE DIFFERENTIATION; LYMPHOCYTOTOXICITY; MELANOMA CELL; MEMORY CELL; PRIORITY JOURNAL; REGULATORY T LYMPHOCYTE; T LYMPHOCYTE SUBPOPULATION; TUMOR CELL DESTRUCTION; COCULTURE; CYTOTOXICITY; DOSE RESPONSE; DRUG EFFECTS; IMMUNOLOGICAL MEMORY; IMMUNOLOGY; MELANOMA; METABOLISM; PATHOLOGY; PHENOTYPE; SKIN NEOPLASMS; TIME FACTOR; TUMOR CELL LINE;

APOPTOSIS; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; CELL LINE, TUMOR; COCULTURE TECHNIQUES; CYTOKINES; CYTOTOXICITY, IMMUNOLOGIC; DOSE-RESPONSE RELATIONSHIP, DRUG; GP100 MELANOMA ANTIGEN; HLA-A2 ANTIGEN; HUMANS; IMMUNOLOGIC MEMORY; MELANOMA; PHENOTYPE; PROTEINS; SINGLE-CHAIN ANTIBODIES; SKIN NEOPLASMS; T-LYMPHOCYTES, REGULATORY; TIME FACTORS;

EID: 85026653080     PISSN: 00192805     EISSN: 13652567     Source Type: Journal    
DOI: 10.1111/imm.12779     Document Type: Article

References (46)

1. Mellman I, Coukos G, Dranoff G. Cancer immunotherapy comes of age. Nature 2011; 480:480–9.
2. Verdeil G, Fuertes Marraco SA, Murray T, Speiser DE. From T cell “exhaustion” to anti-cancer immunity. Biochem Biophys Acta 2016; 1865:49–57.
3. Fridman WH, Pages F, Sautes-Fridman C, Galon J. The immune contexture in human tumours: impact on clinical outcome. Nat Rev Cancer 2012; 12:298–306.
4. Chen DS, Mellman I. Oncology meets immunology: the cancer–immunity cycle. Immunity 2013; 39:1–10.
5. Webster RM. The immune checkpoint inhibitors: where are we now? Nat Rev Drug Discov 2014; 13:883–4.
6. Oates J, Hassan NJ, Jakobsen BK. ImmTACs for targeted cancer therapy: why, what, how, and which. Mol Immunol 2015; 67:67–74.
7. Liddy N, Bossi G, Adams KJ, Lissina A, Mahon TM, Hassan NJ et al. Monoclonal TCR-redirected tumor cell killing. Nat Med 2012; 8:980–7.
8. Joncker NT, Marloie MA, Chernysheva A, Lonchay C, Cuff S, Klijanienko J et al. Antigen-independent accumulation of activated effector/memory T lymphocytes into human and murine tumors. Int J Cancer 2006; 118:1205–14.
9. Kalia V, Sarkar S, Gourley TS, Rouse BT, Ahmed R. Differentiation of memory B and T cells. Curr Opin Immunol 2006; 18:255–64.
10. Lanzavecchia A, Sallusto F. Understanding the generation and function of memory T cell subsets. Curr Opin Immunol 2005; 17:326–32.
11. + T cells. Can Res 2014; 74:705–15.
12. + T cells in immunodeficient mice. Blood 2011; 117:1888–98.
13. + T cells derived from central memory cells establishes persistent T cell memory in primates. J Clin Invest 2008; 118:294–305.
14. + T cells mediate superior antitumor immunity. Proc Natl Acad Sci USA 2009; 106:17469–74.
15. + T cells derived from naive rather than memory subsets possess superior traits for adoptive immunotherapy. Blood 2011; 117:808–14.
16. + effector cell engraftment fitness and function following adoptive transfer. Oncoimmunology 2016; 5:e1072671.
17. + T cells. Eur J Immunol 2014; 44:69–79.
18. + T cells. Clin Exp Immunol 2015; 180:255–70.
19. + T cells are essential for eradicating advanced B-cell lymphoma after chemotherapy. Blood 2012; 120:2229–39.
20. Li Y, Moysey R, Molloy PE, Vuidepot AL, Mahon T, Baston E et al. Directed evolution of human T-cell receptors with picomolar affinities by phage display. Nat Biotechnol 2005; 23:349–54.
21. Boulter JM, Glick M, Todorov PT, Baston E, Sami M, Rizkallah P et al. Stable, soluble T-cell receptor molecules for crystallization and therapeutics. Protein Eng 2003; 16:707–11.
22. McCormack E, Adams KJ, Hassan NJ, Kotian A, Lissin NM, Sami M et al. Bi-specific TCR-anti CD3 redirected T-cell targeting of NY-ESO-1- and LAGE-1-positive tumors. Can Immunol Immunother 2013; 62:773–85.
23. + T cells. J Exp Med 2001; 194:1711–9.
24. Sallusto F, Geginat J, Lanzavecchia A. Central memory and effector memory T cell subsets: function, generation, and maintenance. Annu Rev Immunol 2004; 22:745–63.
25. Marshall NB, Swain SL. Cytotoxic CD4 T cells in antiviral immunity. J Biomed Biotechnol 2011; 2011:954602.
26. + T cells in the priming and effector/memory phases of adoptive immunotherapy. J Immunol 2000; 165:4246–53.
27. + T cells differentiated in vivo eradicate established melanoma. J Exp Med 2010; 207:651–67.
28. Schroder K, Hertzog PJ, Ravasi T, Hume DA. Interferon-γ: an overview of signals, mechanisms and functions. J Leukoc Biol 2004; 75:163–89.
29. Croft M. The role of TNF superfamily members in T-cell function and diseases. Nat Rev Immunol 2009; 9:271–85.
30. Maurer M, von Stebut E. Macrophage inflammatory protein-1. Int J Biochem Cell Biol 2004; 36:1882–6.
31. Cook-Mills JM, Deem TL. Active participation of endothelial cells in inflammation. J Leukoc Biol 2005; 77:487–95.
32. Middleton MR, Steven N, Evans J, Infante J, Sznol M, Mulatero C et al. Safety, pharmacokinetics and efficacy of IMCgp100, a first-in-class soluble TCR Anti-CD3 bispecific T cell redirector with solid tumour activity: results from the FIH study in melanoma. Clin Oncol (R Coll Radiol) 2016; 34:abstract 3016.
33. Herbst RS, Soria JC, Kowanetz M, Fine GD, Hamid O, Gordon MS et al. Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients. Nature 2014; 515:563–7.
34. Nath A, Chattopadhya S, Chattopadhyay U, Sharma NK. Macrophage inflammatory protein (MIP)1α and MIP1β differentially regulate release of inflammatory cytokines and generation of tumoricidal monocytes in malignancy. Can Immunol Immunother 2006; 55:1534–41.
35. + T cell efficacy in vaccination and disease. Nat Med 2008; 14:623–8.
36. Seder RA, Darrah PA, Roederer M. T-cell quality in memory and protection: implications for vaccine design. Nat Rev Immunol 2008; 8:247–58.
37. Pages F, Berger A, Camus M, Sanchez-Cabo F, Costes A, Molidor R et al. Effector memory T cells, early metastasis, and survival in colorectal cancer. N Engl J Med 2005; 353:2654–66.
38. Galon J, Costes A, Sanchez-Cabo F, Kirilovsky A, Mlecnik B, Lagorce-Pages C et al. Type, density, and location of immune cells within human colorectal tumors predict clinical outcome. Science 2006; 313:1960–4.
39. Mlecnik B, Tosolini M, Kirilovsky A, Berger A, Bindea G, Meatchi T et al. Histopathologic-based prognostic factors of colorectal cancers are associated with the state of the local immune reaction. J Clin Oncol 2011; 29:610–8.
40. Ladoire S, Mignot G, Dabakuyo S, Arnould L, Apetoh L, Rebe C et al. In situ immune response after neoadjuvant chemotherapy for breast cancer predicts survival. J Pathol 2011; 224:389–400.
41. Bossi G, Buisson S, Oates J, Jakobsen BK, Hassan NJ. ImmTAC-redirected tumour cell killing induces and potentiates antigen cross-presentation by dendritic cells. Can Immunol Immunother 2014; 63:437–48.
42. Gulley JL. Therapeutic vaccines: the ultimate personalized therapy? Hum Vaccin Immunother 2013; 9:219–21.
43. Disis ML, Wallace DR, Gooley TA, Dang Y, Slota M, Lu H et al. Concurrent trastuzumab and HER2/neu-specific vaccination in patients with metastatic breast cancer. J Clin Oncol 2009; 27:4685–92.
44. Wirsing AM, Rikardsen OG, Steigen SE, Uhlin-Hansen L, Hadler-Olsen E. Characterisation and prognostic value of tertiary lymphoid structures in oral squamous cell carcinoma. BMC Clin Pathol 2014; 14:38.
45. Hiraoka N, Ino Y, Yamazaki-Itoh R. Tertiary lymphoid organs in cancer tissues. Front Immunol 2016; 7:244.
46. + regulatory T cells in cancers: a systematic review and meta-analysis. Sci Rep 2015; 5:15179.